← back to search

Zhibo Liu

Beijing National Laboratory for Molecular Sciences · CN
Area of research
Radiology, Nuclear Medicine and Imaging · Oncology
Research interest
Research interests include Radiopharmaceutical Chemistry and Applications, Medical Imaging Techniques and Applications, Peptidase Inhibition and Analysis, and Nanoplatforms for cancer theranostics.
h-index
50
citations
12,974
works
275
NIH funding
primary concept
Chemistry
email

Recent publications

Radiotherapy meets anticancer metallodrugs.
2026cited by 0position: contributordoi
PLAP Targeted Antibody-Radionuclide Conjugate for Theranostics in Pancreatic Cancer.
2026cited by 0position: contributordoi
<sup>89</sup>Zr/<sup>177</sup>Lu-Labeled Radioimmunoconjugates Targeting SORT1 for Cancer Theranostics.
2026cited by 0position: contributordoi
Radiotherapy Activates Drug-Drug Conjugates for Platinum-Based Combinational Chemotherapy.
2026cited by 0position: contributordoi
Boron neutron capture therapy preserves immune cells and induces robust anti-tumour immunity in preclinical mouse model.
2026cited by 0position: contributordoi
Covalent FAPI Imaging-Guided Precision Surgery in Patients with Medullary Thyroid Carcinoma: A Phase II Clinical Trial.
2026cited by 0position: contributordoi
CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma.
2025cited by 14position: contributordoi
Orchestrating intratumoral DC-T cell immunity for enhanced tumor control via radiotherapy-activated TLR7/8 prodrugs in mice.
2025cited by 9position: contributordoi
Radiotherapy-Activated Prodrug: Past, Present and Beyond.
2025cited by 7position: contributordoi
Single atom engineering for radiotherapy-activated immune agonist prodrugs.
2025cited by 6position: contributordoi
A Bis-Boron Amino Acid for Positron Emission Tomography and Boron Neutron Capture Therapy.
2025cited by 6position: contributordoi
Ribosomal Incorporation of Fluorosulfonyloxy-<i>l</i>-Phenylalanine into Macrocyclic Peptides for De Novo Target-Specific Covalent Binders.
2025cited by 3position: contributordoi
Porphyrin-Engineered <sup>125</sup>I-Nanoseeds as a Prototype for Immunogenic Brachytherapy.
2025cited by 3position: contributordoi
NSD2 mediated H3K36me2 promotes pulmonary arterial hypertension by recruiting FOLR1 and metabolism reprogramming
Cellular Signalling 2025cited by 3position: firstdoi
Design, Structure Optimization, and Preclinical Evaluation of <sup>188</sup>Re-Labeled FAPI for Targeted Radionuclide Therapy.
2025cited by 2position: contributordoi
Radiation-induced aerobic oxidation <i>via</i> solvent-derived peroxyl radicals.
2025cited by 2position: contributordoi
Bioinspired transfer methylation enabled by a photoactive reagent.
2025cited by 1position: contributordoi
Tumour-specific bioorthogonal synthesis of proteolysis-targeting chimeras and nanoparticles boosts T cell activity.
2025cited by 0position: contributordoi
Radiolabeled Albumin Bound Fibroblast Activation Protein (FAP) Inhibitor-04 Enhances Precision in Renal Fibrosis Diagnosis via PET Imaging.
2025cited by 0position: contributordoi
Supplementary Table 11 from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma
2025cited by 0position: contributordoi
Supplementary Table 14 from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma
2025cited by 0position: contributordoi
Supplementary Figure 1 from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma
2025cited by 0position: contributordoi
Supplementary Table 5 from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma
2025cited by 0position: contributordoi
Supplementary Figure 2 from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma
2025cited by 0position: contributordoi
Supplementary Table 7 from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma
2025cited by 0position: contributordoi
Supplementary Table 1 from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma
2025cited by 0position: contributordoi
Notification to AttendingPhysician from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma
2025cited by 0position: contributordoi
Clinical Protocol from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma
2025cited by 0position: contributordoi
Supplementary Table 3 from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma
2025cited by 0position: contributordoi
Supplementary Figure 3 from CTR-FAPI PET Enables Precision Management of Medullary Thyroid Carcinoma
2025cited by 0position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 54 papers (2019–2026)Huimin Ma · American Chemical Society4 papers (2020–2020)Siyong Shen · China Agricultural University3 papers (2023–2026)Qirong Xu · Nanchang University2 papers (2019–2025)Hua Xu · Nanchang University2 papers (2019–2025)Yaxin Shi · Shandong University of Traditional Chinese Medicine2 papers (2019–2020) · 2 papers (2018–2020)B. Timothy Baxter · Creighton University2 papers (2018–2020)Zhongming Zhang · Lancaster University2 papers (2023–2023)Yang-Xin Fu · Xiangyang Hospital of Traditional Chinese Medicine2 papers (2025–2025)Qiang Fu · China Southern Power Grid (China)2 papers (2020–2023)Zhen Gu · College of Pharmaceutical Sciences2 papers (2023–2023)Zijian Guo · American Chemical Society2 papers (2024–2026)Xi-Yang Cui · Nanyang Technological University2 papers (2025–2026)Zhi Gu · Peking University2 papers (2024–2024)Daniëlle J. Vugts · Netherlands Center for Occupational Diseases2 papers (2021–2024)Xiang‐Guo Li · Shanghai Medical College of Fudan University2 papers (2021–2024)Zizhu Zhang · Southern Medical University2 papers (2019–2020) · 2 papers (2018–2020) · 2 papers (2018–2020)